At the news
? BEARISHIMPACT 6/10 PRESS-RELEASE filed Jul 21, 2026 at 22:46 ET
Dyne Therapeutics priced an upsized underwritten public offering of 18.3 million shares at $20.50 per share, raising gross proceeds of $375.15 million. The offering will dilute existing shareholders by approximately 9-11% (including the underwriter option) and provides additional cash runway for the company's clinical-stage neuromuscular programs.
- Offering of 18,300,000 shares at $20.50 per share, upsized from original terms.
- Gross proceeds expected to be $375,150,000 before expenses.
- Underwriters have a 30-day option to purchase up to an additional 2,745,000 shares.
- Expected to close on or about July 23, 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access